Bleeding Complications in Patients With Severe Frostbite Injury.


Journal

Journal of burn care & research : official publication of the American Burn Association
ISSN: 1559-0488
Titre abrégé: J Burn Care Res
Pays: England
ID NLM: 101262774

Informations de publication

Date de publication:
05 07 2023
Historique:
medline: 7 7 2023
pubmed: 10 12 2022
entrez: 9 12 2022
Statut: ppublish

Résumé

Frostbite is caused by exposure to cold temperatures and can lead to severe injury resulting in amputations. Tissue plasminogen activator (tPA) is a thrombolytic agent that has demonstrated efficacy preventing amputation in frostbite patients. The goal of frostbite management with tPA is to salvage tissue without causing clinically significant bleeding complication. The purpose of this study was to characterize bleeding complications in severe frostbite patients managed with and without tPA. Retrospective chart review of severe frostbite patients admitted to a single ABA verified burn center. Bleeding events were grouped: category 0: no bleed; category 1: bleed not resulting in change or intervention; category 2: bleed resulting in change of management; and category 3: bleed resulting in change of management and intervention. Over a 7-year period, 188 patients were included in the study. Most patients had no documentation suggesting a bleeding complication: 69.7% category 0, 19.1% category 1, 4.8% category 2, and 6.4% category 3. There was no significant difference in category 2 or 3 bleeding complications between patients treated with or without tPA. Overall, 9 of the 143 patients (6.3%) treated with tPA had a category 2 or 3 bleeding complication within 12 hours of tPA completion and 12 of 143 (8.4%) within 24 hours of tPA completion. Based on the low risk of severe bleeding and significant benefit relative to limb or digit salvage demonstrated in this study, we conclude that tPA is safe and effective for the treatment of frostbite in appropriately selected patients.

Identifiants

pubmed: 36482743
pii: 6884252
doi: 10.1093/jbcr/irac180
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68
Fibrinolytic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

745-750

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Jenna Murphy (J)

Pharmacy Department, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Frederick W Endorf (FW)

Department of Surgery, Hennepin Healthcare, Minneapolis, Minnesota, USA.

M Kenett Winters (MK)

Pharmacy Department, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Charlotte Rogers (C)

Department of Surgery, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Ellen Walter (E)

Pharmacy Department, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Nichole Neumann (N)

Pharmacy Department, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Lynn Weber (L)

Pharmacy Department, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Alexandra M Lacey (AM)

Department of Surgery, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Gopal Punjabi (G)

Department of Radiology, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Rachel M Nygaard (RM)

Department of Surgery, Hennepin Healthcare, Minneapolis, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH